Medical Articles 6/28

Posted by rob on June 28, 2008 under Uncategorized | Be the First to Comment

Medical Articles 6/26

Posted by rob on June 26, 2008 under Uncategorized | Be the First to Comment

Current and emerging tests for the laboratory monitoring of chronic myeloid leukaemia and related disorders.

Information is temporarily unavailable.

Tell haematologists there’s been no progress in CML and … see ‘em yell!

Information is temporarily unavailable.

Monosomy 7 in t(9;22)-negative cells during nilotinib therapy in an imatinib-resistant chronic myeloid leukemia case.

Information is temporarily unavailable.

A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript.

Medical Articles 6/25

Posted by rob on June 25, 2008 under Uncategorized | Be the First to Comment

Cochlear implantation in complete remission in a patient with leukemia.

Information is temporarily unavailable.

Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells.

Information is temporarily unavailable.

Interferon-alpha is able to maintain complete molecular remission induced by imatinib after its discontinuation.

Information is temporarily unavailable.

Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation.

Information is temporarily unavailable.

MT1-MMP as a downstream target of BCR-ABL/ABL interactor 1 signaling: polarized distribution and involvement in BCR-ABL-stimulated leukemic cell migration.

Medical Articles 6/22

Posted by rob on June 22, 2008 under Uncategorized | Be the First to Comment

 Dynamics and potential impact of the immune response to chronic myelogenous leukemia.

Information is temporarily unavailable.

BCR-ABL in Chronic Myelogenous Leukemia – How Does It Work?

Information is temporarily unavailable.

Osteonecrosis in adult survivors of childhood cancer: a report from the childhood cancer survivor study.

Information is temporarily unavailable.

[Novel medical treatment modalities in hematology]

Information is temporarily unavailable.

Chronic myeloid leukemia stem cells.

Information is temporarily unavailable.

Mathematical models of cancer stem cells.

Information is temporarily unavailable.

Part I: Milestones in personalised medicine–imatinib.

Information is temporarily unavailable.

Commentary: Novel therapies for cancer: why dirty might be better.

Information is temporarily unavailable.

Rho GTPases and regulation of hematopoietic stem cell localization.

Medical Articles 6/20

Posted by rob on June 20, 2008 under Uncategorized | Be the First to Comment

Advances in the biology and therapy of acute myelogenous leukemia. Selection of keynote addresses from the Acute Leukemia Forum 2007. March 23, 2007. San Francisco, California, USA.

Information is temporarily unavailable.

Molecular and cytogenetic response of chronic myelogenous leukemia treated with imatinib mesylate: one institutional experience in Japan.

Information is temporarily unavailable.

Serine/arginine protein-specific kinase 2 promotes leukemia cell proliferation by phosphorylating acinus and regulating cyclin A1.

Information is temporarily unavailable.

Stem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL kinase inhibitors.

Information is temporarily unavailable.

Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS.

Medical Articles 6/15

Posted by rob on June 15, 2008 under Uncategorized | Be the First to Comment

PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.

In
Vitro Induction of a Dendritic Cell Phenotype in Primary Human Acute
Myelogenous Leukemia (AML) Blasts Alters the Chemokine Release Profile
and Increases the Levels of T Cell Chemotactic CCL17 and CCL22.

Medical Articles 6/11

Posted by rob on June 11, 2008 under Uncategorized | Be the First to Comment

No
significance of derivative chromosome 9 deletion on the clearance
kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular
response, loss of response, or treatment failure to imatinib mesylate
therapy for chronic myeloid leukemia.

Sequential
mutations causing resistance to both Imatinib Mesylate and Dasatinib in
a chronic myeloid leukaemia patient progressing to lymphoid blast
crisis.

Medical Articles 6/4

Posted by rob on June 4, 2008 under Uncategorized | Be the First to Comment

Adiponectin
and resistin are associated with risk for myelodysplastic syndrome,
independently from the insulin-like growth factor-I (IGF-I) system.

Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib.